Mission and Vision
Innovative challenges
to healthier longevity
Klotho Sciences is committed to developing innovative therapeutics that restore mitochondrial function and activate key longevity proteins to overcome degenerative diseases and extend healthy lifespan. Our mission is to address aging itself and its associated diseases through science, ultimately improving the quality of life for patients and their families.
Global leader in innovative new drugs
that restore the expression of the Klotho protein
Unmet medical needs Providing new treatments for diseases
1. First-in-Class, Klotho Protein Expression Restoration Drug Discovery
2. Leader in the development of Klotho drugs for aging and degenerative diseases
3. Building a global open-ended Klotho R&BD platform
About us
History
2024
Selected as a Resident Company at Seoul Biohub Global Center
KS101 Complete GLP toxicology and nonclinical studies
2023
Selected for Deep Tech TIPS (Non-Clinical Completed Projects, 1.5 billion)
Selected for the K-BioHealth Support Project at Seoul National University Bundang
Hospital
(3 consecutive years)
KS104 Compound Patent Registered
2022
Selected for K-BioHealth Support Project at Seoul National University Bundang Hospital
KS101 AD Patent Registered
KS101 CKD Patent Registered
2021
Identify new candidates (KS102-104)
Efficacy of KS101 in AD Confirmed
Efficacy of KS101 in AD Confirmed
2020
Founding Klotho Sciences
Recognition of Corporate Affiliated Research Centers
2020
Klotho Drug Candidate(KS101) Secured
Our Executive Team & Scientific Advisory Board (SAB)
Klotho Sciences is driven by a team of exceptional and seasoned leaders and researchers. Our strategic focus lies in developing our 100-series compounds to address the critical unmet needs in Alzheimer’s Disease (AD) and Chronic Kidney Disease (CKD). To ensure the seamless translation of our scientific advancements into clinical applications, we maintain close collaboration with a distinguished Scientific Advisory Board comprised of leading AD or CKD specialists.
Dongju Jung,
Ph.D. CEO
Scientist, developed KS101 and KS100-series compounds
- • (Current) Professor at Hoseo University, South Korea
- • Oklahoma University Medical School, USA
- • iCeMS Laboratory, Kyoto University, Japan
- • Baylor College of Medicine, USA
- • LG Chem Biotech institute
Youn Hoon Joo, M.D., Ph.D.
Global BD expert
- • PwC Partner, Bio/Healthcare/Pharmaceutical Industry Leader(Korea)
- • Executive vice president in Samsung Corp.
- • Executive director in Samsung medical center
- • Seoul National University Hospital, department of Family Medicine
- • M.D., Ph.D., Seoul National University, College of Medicine
Hyunggi Lee, M.D., Ph.D
Global Clinical Expert
- • (Current) Professor, Department of Clinical Pharmacology, Seoul National University Hospital, Seoul, South Korea
- • Associate Professor, University of California San Francisco
- • Center for Drug Development Science, UCSF, Director
- • Univ. of Pittsburgh Assistant Professor
- • M.D., Ph.D., Seoul National University, College of Medicinen
Kyeong-Ryoon Lee, Ph.D
PK/PD expert
- • (Current) Senior researcher at Korea Research Institute of Bioscience and Biotechnology, Ochang, South Korea
- • Head Professor, Department of Biotechnology, Korea University of Science and Technology (UST)
- • Adjunct associate professor, Graduate School of Convergence Science and Technology, Seoul National University/li>
- • Post-Doc, College of Pharmacy, New Jersey State University, USA.
- • Ph.D., Seoul National University, College of Pharmacy
Sangyoon Kim, M.D., Ph.D.
Global Clinical Expert
- • (Current) Professor of Neurology, Seoul National University Bundang Medical Center, Seongnam, South Korea
- • Editorial Board Member, Journal of Alzheimer's disease
- • Scientific Director, Alzheimer's Association
- • Director of Research, Korean Geriatrics Society
- • M.D., Ph.D., Seoul National University, College of Medicine
Sejoong Kim, M.D., Ph.D.
Global Clinical Expert
- • (Current) Professor of Nephrology, Seoul National University Bundang Medical Center, Seongnam, South Korea
- • Member of the Korean Society of Nephrology
- • Fellow of the American Society of Nephrology
- • M.D., Ph.D., Seoul National University, College of Medicine
GLP Tox
Corestemchemon
- Established in 2003
the first private nonclinical testing company in the Republic of Korea.
https://www.corestemchemon.com/eng/main/main.html
CMC
Mayne Pharma
- Established in 2005, Australia.
https://www.maynepharma.com
KB Pharma
- Established in 1987. Research Center for researching and developing APIs medicines in the Republic
of Korea.
https://www.kbpharma.co.kr/en/home
DMPK
KRIBB*
- Established in 1985. a government-affiliated institute
https://www.kribb.re.kr/eng2/main/main.jsp
*Korea Research Institute of Bio science and Bio technology
CRO
Southern Star Research
- Established in 2010, Australia. Australian Clinical Trials CRO
https://southernstarresearch.com
Novotech
- Establishedin 1997. Global full-service CRO
https://novotech-cro.com/
Please send an inquiry email to the business development representative below.
Company name
Klotho Sciences, Inc.
Location
407, 117-3, Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea
1stResearch Center : #110, Health Center, 20, Hoseo-ro 79beon-gil, Asan-si, Chungcheongnam-do, Korea
2ndR&D Center : 3F, 172,Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do,Republic of Korea
Contact us
Dongju Jung
shj@klothosciences.com